The Food and Drug Administration approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA ...

The opioid industry in China is expected to rise at a CAGR of 3.3% through 2034. Based on application, the analgesia segment hold a 6.6% market share in 2024. The hospital pharmacies segment ...

A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...

Opioids reduce pain by binding to receptors in the brain that receive nerve signals from different parts of the body. Those chemical interactions also give rise to opioids' addictive effects.

Rather, he seemed to favor 12-step recovery programs, which have not been properly assessed for their impact on opioid users ... in fentanyl deaths is on the rise. Xylazine is a type of ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

Opioids reduce pain by binding to receptors in the brain that receive nerve signals from different parts of the body. Those chemical interactions also give rise to opioids’ addictive effects.

Opioids reduce pain by binding to receptors in the brain that receive nerve signals from different parts of the body. Those chemical interactions also give rise to opioids’ addictive effects.

Journavx (suzetrigine), a non-opioid pill for moderate-to-severe acute pain, has just received FDA approval. It’s the first drug in a new family of medicines that block pain signals before they ...

LOS ANGELES, CALIFORNIA - FEBRUARY 02: Melissa Etheridge (L) performs with Megan Lovell (R) of ... [+] Larkin Poe onstage during the 2024 MusiCares Person of the Year Honoring Jon Bon Jovi during ...